

Supplementary Tables

Supp. Table 1: Clinical and epidemiological characteristics of sub-study participants and PIVOT patients not recruited for the sub-study at participating sites

	Sub-study participants (N=146)	Patients Not recruited (N=73)
PI-mono, N (%)	75 (51)	38 (52)
Age, Median (IQR) †	47.7 (41.1; 53.2)	42.2 (37.4; 48.9)
Sex, N (%)		
Male	126 (86)	57 (78)
Ethnicity, N (%)		
White	119 (82)	52 (71)
Black	22 (15)	17 (23)
Other	5 (3)	4 (6)
Smokers at study entry, N (%)	35 (24)	16 (22)
Years of formal education, Median (IQR)	15 (12; 18)	15 (13; 18)
CD4 cell count nadir, Median (IQR)	180 (90; 260)	181 (91; 240)
CD4 cell count at final PIVOT visit, Median (IQR)	640 (483; 785)	644 (550; 860)
HIV-RNA <50 copies/ml at final PIVOT visit, N (%)*	139 (95)	64 (88)
Moderate/severe anxiety or depression, N (%)	50 (34)	24 (42)
NPZ-5 score at final PIVOT visit, Median (IQR)	0.1 (-0.4; 0.6)	-0.1 (-0.6; 0.3)

†p<0.001; *p=0.05

Supp. Table 2a. Recreational drugs use by study arm, N (%)

	PI-mono (N=74)	OT (N=68)	TOTAL (N=142)
No recreational drugs use	23 (31.1)	19 (27.9)	42 (29.6)
Recreational drugs use (in the past)	26 (35.1)	30 (44.1)	56 (39.4)
Recreational drugs use (currently)	25 (33.8)	19 (27.9)	44 (31.0)

Supp. Table 2b. Recreational drugs use by study arm, N (%)

	Never		Past		Current	
	PI-mono	OT	PI-mono	OT	PI-mono	OT
GBL/GHB	60 (80.0)	60 (84.1)	11 (14.7)	5 (7.0)	4 (5.3)	6 (8.5)
Cocaine	47 (62.7)	45 (63.4)	24 (32.0)	18 (25.4)	4 (5.3)	8 (11.3)
Crystal Meth	67 (89.3)	65 (91.6)	5 (6.7)	4 (5.6)	3 (4.0)	2 (2.8)
Mephedrone	61 (81.3)	62 (87.3)	13 (17.3)	6 (8.5)	1 (1.3)	3 (4.2)
Cannabis	49 (65.3)	42 (59.1)	21 (28.0)	22 (31.0)	5 (6.7)	7 (9.9)
Ketamine	57 (76.0)	57 (80.3)	15 (20.0)	9 (12.7)	3 (4.0)	5 (7.0)
Ecstasy	51 (68.0)	46 (64.8)	23 (30.7)	19 (26.8)	1 (1.3)	6 (8.5)
Legal highs	70 (93.3)	69 (97.2)	5 (6.7)	2 (2.8)	0	0
Other*	67 (89.3)	51 (71.8)	8 (10.7)	18 (25.4)	0	2 (2.8)

*Fisher's exact p-value: 0.013

Supp. Table 3. Correlation between neuropsychological test Z-scores (Pearson coefficients)

	HVLT-L	HVLT-R	CTT-1	CTT-2	GPT	FTT	DST	RCFT-I	RCFT-D	SCWT
HVLT-L	1.0000									
HVLT-R	0.7081	1.0000								
CTT-1	0.1601	0.1348	1.0000							
CTT-2	0.2830	0.2260	0.6641	1.0000						
GPT	0.3467	0.2496	0.4646	0.3270	1.0000					
FTT	0.0980	0.1841	0.1998	0.1559	0.2252	1.0000				
DST	0.4229	0.3457	0.4491	0.4857	0.5015	0.2484	1.0000			
RCFT-L	0.3955	0.4454	0.0509	0.1222	0.2045	0.3014	0.3338	1.0000		
RCFT-R	0.3487	0.4005	0.0473	0.0839	0.1978	0.3055	0.2848	0.9094	1.0000	
SCWT	0.1847	0.1663	0.5355	0.5665	0.4143	0.2779	0.6455	0.1461	0.1034	1.0000

HVLT-L: Hopkins Verbal Learning Test Learning trials; HVLT-R: Hopkins Verbal Learning Test delayed recall trial; CTT-1: Color Trail Test part 1; CTT-2: Color Trail Test part 2; GPT: Grooved Pegboard Test; FTT: Finger Tapping Test; DST: Digit Symbol Test; RCFT-I: Rey Complex Figure Test Immediate Recall; RCFT-D: Rey Complex Figure Test Delayed Recall; SCWT: Stroop Color and word Test

Supp Table 4: Clinical and epidemiological characteristics of sub-study participants with and without neuroimaging data

	Participants with Neuroimaging (N=78)	Participants without Neuroimaging (N=68)
PI-mono, N (%)	39 (50)	36 (53)
Switched away from randomised allocation, N (%)	13 (17)	19 (28)
Age, Median (IQR)	48.2 (40.3; 53.0)	47.1 (41.8; 53.3)
Sex, N (%)		
Male	65 (83)	61 (90)
Ethnicity, N (%)		
White	65 (83)	54 (80)
Black	11 (14)	11 (16)
Other	2 (4)	3 (4)
Smokers at study entry, N (%)	21 (27)	14 (21)
Years of formal education, Median (IQR)	15 (12; 18)	15 (13; 18)
CD4 cell count nadir, Median (IQR)	170 (70; 250)	184 (101; 272)
CD4 cell count at sub-study visit, Median (IQR)	640 (490; 785)	642 (461; 788)
HIV-RNA <50 copies/ml at final PIVOT visit, N (%)	72 (96)	67 (99)
Moderate/severe anxiety or depression, N (%)	26 (33)	24 (35)
NPZ-5 score at final PIVOT visit, Median (IQR)	0.1 (-0.3; 0.6)	0.1 (-0.6; 0.5)